FDA clears first treatment for Prader-Willi syndrome Soleno Therapeutics' Vykat XR has become the first FDA-approved treatment for excessive eating in rare disorder Prader-Willi syndrome.

NEWS: #SolenoTherapeutics' #VykatXR has become the first FDA-approved treatment for #PraderWillisyndrome (PWS), a rare #geneticdisorder that causes excessive appetite and obesity.

pharmaphorum.com/news/fda-cle...